Antibodies against nogo receptor
The present invention relates to antibodies and related molecules that specifically bind to the Nogo receptor (NogoR). Such antibodies have uses, for example, in the treatment of spinal cord injury, brain trauma, paralysis, degenerative nervous system diseases, and stroke. The invention also relates to nucleic acid molecules encoding anti-NogoR antibodies, vectors and host cells containing these nucleic acids, and methods for producing the same.
1. An isolated single chain antibody comprising amino acids 31-36 (VH CDR1), 51-66 (VH CDR2), 99-110 (VH CDR3), 160-173 (VL CDR1), 189-195 (VL CDR2) and 228-238 (VL CDR3) of SEQ ID NO: 65, wherein the antibody specifically binds the polypeptide of SEQ ID NO: 2 (NogoR).
2. An isolated single chain antibody comprising the VH and VL domains of the amino acid sequence of SEQ ID NO: 65, wherein the antibody specifically binds the polypeptide of SEQ ID NO: 2 (NogoR).
3. The isolated antibody of claim 2 , wherein the antibody consists of the amino acid sequence of SEQ ID NO: 65.
4. The antibody of claim 3 , wherein the antibody binds the polypeptide of SEQ ID NO: 2 (NogoR) purified from a cell culture, wherein the cells in the cell culture comprise a polynucleotide encoding amino acids 1 to 473 of SEQ ID NO:2operably associated with a regulatory sequence that controls gene expression.
5. The antibody of claim 3 , wherein the antibody prevents binding or inhibits interaction of NogoR with a molecule selected from the group consisting of:
(a) p75(NTR);
(b) LINGO-1;
(c) Nogo;
(d) Omgp; and
(e) MAG.
6. The antibody of claim 3 , wherein the antibody promotes neurite outgrowth or axonal regeneration.
7. The antibody of claim 2 , wherein the antibody binds the polypeptide of SEQ ID NO: 2 (NogoR) purified from a cell culture, wherein the cells in the cell culture comprise a polynucleotide encoding amino acids 1 to 473 of SEQ ID NO: 2 operably associated with a regulatory sequence that controls gene expression.
8. The antibody of claim 2 , wherein the antibody prevents binding or inhibits interaction of NogoR with a molecule selected from the group consisting of:
(a) p75(NTR);
(b) LINGO-1;
(c) Nogo;
(d) Omgp; and
(e) MAG.
9. The antibody of claim 2 , wherein the antibody promotes neurite outgrowth or axonal regeneration.
10. The antibody of claim 2 , wherein the antibody is conjugated to a detectable label.
11. The antibody of claim 2 , wherein the antibody is biotinylated.
12. The antibody of claim 2 , wherein the antibody is conjugated to a therapeutic or cytotoxic agent.
13. The antibody of claim 2 , wherein the antibody specifically binds NogoR in a Western blot.
14. The antibody of claim 2 , wherein the antibody specifically binds NogoR in an ELISA assay.
15. An isolated cell that produces the antibody of claim 2 .